Malviya M, Aretz ZEH, Molvi Z, Lee J, Pierre S, Wallisch P, Dao T, Scheinberg DA.  2023.  Challenges and solutions for therapeutic TCR-based agents.. Immunol Rev. 320(1):58-82.

Bourne CM, Wallisch P, Dacek MM, Gardner TJ, Pierre S, Vogt K, Corless BC, Bah MA, Romero-Pichardo JE, Charles A et al..  2023.  Host Interactions with Engineered T-cell Micropharmacies.. Cancer Immunol Res. 11(9):1253-1265.

Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M et al..  2017.  A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.. J Clin Invest. 127(7):2705-2718.

Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA.  2016.  Opportunities and challenges for TCR mimic antibodies in cancer therapy.. Expert Opin Biol Ther. 16(8):979-87.

Levine AG, Arvey A, Jin W, Rudensky AY.  2014.  Continuous requirement for the TCR in regulatory T cell function.. Nat Immunol. 15(11):1070-8.

Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA.  2013.  Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression.. Mol Ther. 21(5):1055-63.

Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sandoval C, Balamurugan A, Yang OO, Zack JA.  2012.  In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.. PLoS Pathog. 8(4):e1002649.

Wang Y, Kissenpfennig A, Mingueneau M, Richelme S, Perrin P, Chevrier S, Genton C, Lucas B, DiSanto JP, Acha-Orbea H et al..  2008.  Th2 lymphoproliferative disorder of LatY136F mutant mice unfolds independently of TCR-MHC engagement and is insensitive to the action of Foxp3+ regulatory T cells.. J Immunol. 180(3):1565-75.